Atea Pharmaceuticals

Atea Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
2014-01-01
Employees
75
Market Cap
$324.1M
Website
http://www.ateapharma.com
Clinical Trials
Related News

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

Phase 1
Terminated
Conditions
Dengue
Interventions
Drug: Placebo Comparator
Drug: AT-752
First Posted Date
2022-05-09
Last Posted Date
2023-04-21
Lead Sponsor
Atea Pharmaceuticals, Inc.
Target Recruit Count
5
Registration Number
NCT05366439
Locations
🇺🇸

Atea Study Site, Syracuse, New York, United States

Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal

First Posted Date
2022-02-25
Last Posted Date
2022-10-18
Lead Sponsor
Atea Pharmaceuticals, Inc.
Target Recruit Count
136
Registration Number
NCT05256732
Locations
🇨🇦

Atea Study Site, Québec, Montreal, Quebec, Canada

Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)

Phase 1
Completed
Conditions
Healthy Volunteer Study
Interventions
Drug: AT-527 + rosuvastatin
First Posted Date
2021-12-10
Last Posted Date
2022-02-25
Lead Sponsor
Atea Pharmaceuticals, Inc.
Target Recruit Count
29
Registration Number
NCT05154123
Locations
🇨🇦

Atea Study Site, Québec, Montreal, Quebec, Canada

Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)

Phase 1
Completed
Conditions
Healthy Volunteers Study
Interventions
Drug: AT-527 + digoxin
First Posted Date
2021-11-30
Last Posted Date
2022-02-28
Lead Sponsor
Atea Pharmaceuticals, Inc.
Target Recruit Count
29
Registration Number
NCT05137626
Locations
🇨🇦

Atea Study Site, Montreal, Quebec, Canada

Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)

Phase 1
Completed
Conditions
Healthy Volunteer Study
Interventions
Drug: AT-527 (R07496998)
First Posted Date
2021-08-13
Last Posted Date
2022-02-25
Lead Sponsor
Atea Pharmaceuticals, Inc.
Target Recruit Count
6
Registration Number
NCT05004415
Locations
🇺🇸

Atea Study Site, Lincoln, Nebraska, United States

Bronchopulmonary PK of AT-527 (R07496998)

Phase 1
Completed
Conditions
Healthy Volunteer Study
Interventions
Drug: AT-527
First Posted Date
2021-05-07
Last Posted Date
2022-02-25
Lead Sponsor
Atea Pharmaceuticals, Inc.
Target Recruit Count
24
Registration Number
NCT04877769
Locations
🇬🇧

Atea Study Site, London, United Kingdom

Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)

Phase 1
Completed
Conditions
Healthy Volunteer Study
Interventions
Drug: AT-527 550 mg + midazolam
First Posted Date
2021-04-29
Last Posted Date
2021-07-29
Lead Sponsor
Atea Pharmaceuticals, Inc.
Target Recruit Count
24
Registration Number
NCT04865445
Locations
🇨🇦

Atea Study Site, Montreal, Montreal, Quebec, Canada

Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)

Phase 1
Completed
Conditions
Healthy Volunteer Study
Interventions
Drug: AT-527 550 mg + cyclosporine
First Posted Date
2021-04-19
Last Posted Date
2021-08-02
Lead Sponsor
Atea Pharmaceuticals, Inc.
Target Recruit Count
24
Registration Number
NCT04849299
Locations
🇨🇦

Atea Study Site, Montreal, Quebec, Canada

Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

Phase 1
Completed
Conditions
Healthy Volunteer Study
First Posted Date
2021-03-05
Last Posted Date
2021-07-29
Lead Sponsor
Atea Pharmaceuticals, Inc.
Target Recruit Count
20
Registration Number
NCT04784000
Locations
🇨🇦

Atea Study Site, Montreal, Quebec, Canada

Study of AT-752 in Healthy Subjects

Phase 1
Completed
Conditions
Dengue
Interventions
Drug: Placebo
Drug: AT-752
First Posted Date
2021-01-25
Last Posted Date
2022-10-17
Lead Sponsor
Atea Pharmaceuticals, Inc.
Target Recruit Count
65
Registration Number
NCT04722627
Locations
🇦🇺

Atea Study Site, Melbourne, Victoria, Australia

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy